BioCentury
ARTICLE | Clinical News

MLE4901: Phase IIa data

August 8, 2016 7:00 AM UTC

A double-blind, international Phase IIa trial in 65 patients with PCOS showed that twice-daily 40 mg MLE4901 met the primary endpoint of reducing serum LH concentration from baseline to day 7 vs. plac...